In the former study, it was found that in mutant BRAF melanoma cells with acquired vemurafenib-resistance mediated by secondary mutation in NRAS, PB04 inhibited the phosphorylation of ERK1/2, while in the latter study, it was observed that the acquired resistance to B-RAF inhibitor developed through NRAS mutations. The gene discussed is NRAS; the disease is melanoma.